Browsing by Author "Yuksel, H."
Now showing items 1-6 of 6
-
Does atopy affect the course of viral pneumonia?
Erdem, S. B.; Can, D.; Girit, S.; Catal, F.; Sen, V.; Pekcan, S.; Yuksel, H. (Elsevier Espana Slu, 2018)Background: The presence of atopy is considered as a risk factor for severe respiratory symptoms in children. The objective of this study was to examine the effect of atopy on the course of disease in children hospitalised ... -
Fibrosis in heart failure subtypes
Toprak, G.; Yuksel, H.; Demirpence, O.; Islamoglu, Y.; Evliyaoglu, O.; Mete, N. (Verduci Publisher, 2013)BACKGROUND: The differences in concentrations of biomarkers between heart failure patients with dilated cardiomyopathy (HF-D) and with ischemic cardiomyopathy (HF-I) have yet to be defined. The objectives of this study ... -
The Protective Effect of Ellagic Acid on Lung Damage Caused by Experimental Obstructive Jaundice Model
Gul, M.; Aliosmanoglu, I.; Uslukaya, O.; Firat, U.; Yuksel, H.; Gumus, M.; Ulger, B. V. (Acta Medical Belgica, 2013)Aim : This study aimed to investigate protective effects of ellagic acid on lungs in an experimental obstructive jaundice model. Methods : Four groups were established, each consisting of ten randomly selected rats : Group ... -
The protective effects of pomegranate on liver and remote organs caused by experimental obstructive jaundice model
Yilmaz, E. E.; Arikanoglu, Z.; Turkoglu, A.; Kilic, E.; Yuksel, H.; Gumus, M. (Verduci Publisher, 2016)OBJECTIVE: We aimed to investigate the protective potential of pomegranate extract on the liver and remote organs in rats with obstructive jaundice. MATERIALS AND METHODS: The rats were split into 4 groups. In Group 1 (G1) ... -
SERUM COENZYME-Q10 ACTIVITY AND OXIDATIVE STATUS IN PATIENTS WITH FIBROMYALGIA
Bozkurt, M.; Oktayoglu, P.; Ucar, D.; Em, S.; Caglayan, M.; Yuksel, H.; Batmaz, I. (Bmj Publishing Group, 2013)[Abstract Not Available] -
Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity
Sahin, A.; Gursel-Ozkurt, Z.; Sahin, M.; Turkcu, F. M.; Yildirim, A.; Yuksel, H. (Springer London Ltd, 2018)We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. The ...